

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<i>In re</i> application of: BORUNDA, J. et al. Appl. No. 10/724,292 Filed: 1 December 2003 For: Recombinant Adenoviral Vectors And Their Utility In The Treatment Of Various Types Of Fibrosis: Hepatic, Renal, Pulmonary, As Well As Hypertrophic Scars	Art Unit: 1632 Examiner: CHEN, S. L. Atty. Docket: 061537-0036US Confirmation No.: 4513 Customer No.: 09629
--	---

RESPONSE TO FINAL OFFICE ACTION

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This communication is being submitted in response to the Non-Final Office Action of 15 January 2009.

Applicants do not believe that any extensions of time are necessary to maintain the pendency of this application beyond what may be submitted herewith. If, however, any additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. §1.136(a), and any fees required, including fees for net addition of claims, are hereby authorized to be charged to Deposit Account No. 50-0310.

Amendments to the claims begin on page 2.

Remarks begin on page 3.